Ãslaug Helland

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/5038502/publications.pdf

Version: 2024-02-01

207	8,756	61687	56606
papers	citations	45 h-index	87 g-index

272	272	272	16659
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Epigenomeâ€wide threeâ€way interaction study identifies a complex pattern between TRIM27, KIAA0226, and smoking associated with overall survival of earlyâ€stage NSCLC. Molecular Oncology, 2022, 16, 717-731.	2.1	4
2	Common variants in breast cancer risk loci predispose to distinct tumor subtypes. Breast Cancer Research, 2022, 24, 2.	2.2	15
3	Final efficacy and safety data, and exploratory molecular profiling from the phase III ALUR study of alectinib versus chemotherapy in crizotinib-pretreated ALK-positive non-small-cell lung cancer. ESMO Open, 2022, 7, 100333.	2.0	16
4	Serum RNAs can predict lung cancer up to 10 years prior to diagnosis. ELife, 2022, 11, .	2.8	14
5	Prognostic Significance of the Loss of Heterozygosity of KRAS in Early-Stage Lung Adenocarcinoma. Frontiers in Oncology, 2022, 12, 873532.	1.3	3
6	A national precision cancer medicine implementation initiative for Norway. Nature Medicine, 2022, 28, 885-887.	15.2	7
7	Improving public cancer care by implementing precision medicine in Norway: IMPRESS-Norway. Journal of Translational Medicine, 2022, 20, 225.	1.8	7
8	Proteome Analysis of Pancreatic Tumors Implicates Extracellular Matrix in Patient Outcome. Cancer Research Communications, 2022, 2, 434-446.	0.7	1
9	Prototype precision oncology learning ecosystem: Norwegian precision cancer medicine implementation initiative.. Journal of Clinical Oncology, 2022, 40, e13634-e13634.	0.8	2
10	Handling missing MRI sequences in deep learning segmentation of brain metastases: a multicenter study. Npj Digital Medicine, 2021, 4, 33.	5.7	31
11	P17.02 Durvalumab After chemoRadioTherapy (DART) for NSCLC Patients â€“ a Phase II Translational and Biomarker Study. Journal of Thoracic Oncology, 2021, 16, S351-S352.	0.5	1
12	COVID-19 in Cancer Patients, Risk Factors for Disease and Adverse Outcome, a Population-Based Study From Norway. Frontiers in Oncology, 2021, 11, 652535.	1.3	38
13	OA01.07 A Phase II Study of the Oral Selective AXL Inhibitor Bemcentinib with Pembrolizumab in Patients with Advanced NSCLC. Journal of Thoracic Oncology, 2021, 16, S103.	0.5	2
14	P24.07 Nivolumab and Ipilimumab +/- UV1 Vaccination as 2nd Line Treatment in Patients with Malignant Mesothelioma (the NIPU-Study). Journal of Thoracic Oncology, 2021, 16, S380.	0.5	0
15	63MO Safety analysis of durvalumab following stereotactic body radiotherapy (SBRT) in early-stage non-small cell lung cancer (NSCLC) patients: A first report of a randomized phase II trial (ASTEROID). Journal of Thoracic Oncology, 2021, 16, S729-S730.	0.5	4
16	NIPU: a randomised, open-label, phase II study evaluating nivolumab and ipilimumab combined with UV1 vaccination as second line treatment in patients with malignant mesothelioma. Journal of Translational Medicine, 2021, 19, 232.	1.8	9
17	Age-related treatment patterns for stage I NSCLC in three European countries. Journal of Geriatric Oncology, 2021, 12, 1214-1219.	0.5	10
18	Lung Function After Stereotactic Body Radiation Therapy for Early-Stage Non-Small Cell Lung Cancer, Changes and Predictive Markers. Frontiers in Oncology, 2021, 11, 674731.	1.3	10

#	Article	IF	Citations
19	Real-world treatment outcomes with brigatinib in patients with pretreated ALK+ metastatic non-small cell lung cancer. Lung Cancer, 2021, 157, 9-16.	0.9	7
20	Association of germline genetic variants with breast cancer-specific survival in patient subgroups defined by clinic-pathological variables related to tumor biology and type of systemic treatment. Breast Cancer Research, 2021, 23, 86.	2.2	7
21	MRI pulse sequence integration for deepâ€learningâ€based brain metastases segmentation. Medical Physics, 2021, 48, 6020-6035.	1.6	6
22	Mendelian randomisation study of smoking exposure in relation to breast cancer risk. British Journal of Cancer, 2021, 125, 1135-1145.	2.9	9
23	Rovalpituzumab Tesirine as a Maintenance Therapy After First-Line Platinum-Based Chemotherapy in Patients With Extensive-Stageâ€“SCLC: Results From the Phase 3 MERU Study. Journal of Thoracic Oncology, 2021, 16, 1570-1581.	0.5	65
24	Dynamic changes in the T cell receptor repertoire during treatment with radiotherapy combined with an immune checkpoint inhibitor. Molecular Oncology, 2021, 15, 2958-2968.	2.1	5
25	Intracranial effect of osimertinib in relapsed EGFR-mutated T790M-positive and -negative non-small cell lung cancer patients: results from a phase II study. Acta OncolÃ³gica, 2021, 60, 1565-1571.	0.8	2
26	1795P Gender difference in side effects of immunotherapy: A possible clue to optimize cancer treatment. Annals of Oncology, 2021, 32, S1223-S1224.	0.6	4
27	P59.18 Evaluation of ROS1 Expression in a Large Cohort of Early Stage Lung Cancer. Journal of Thoracic Oncology, 2021, 16, S1155-S1156.	0.5	0
28	P59.15 Is CD73 Expression a Druggable Mechanism of Resistance in EGFR-TKI-Treated EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC)?. Journal of Thoracic Oncology, 2021, 16, S1154.	0.5	0
29	P28.03 Durvalumab Adjuvant to Chemoradiation for Patients With Locally Advanced Non-Small Cell Lung Cancer: Real World Experience. Journal of Thoracic Oncology, 2021, 16, S1045.	0.5	0
30	Whole genome copy number analyses reveal a highly aberrant genome in TP53 mutant lung adenocarcinoma tumors. BMC Cancer, 2021, 21, 1089.	1.1	3
31	Immune checkpoint blockade in the treatment of advanced non-small cell lung cancer â€“ predictors of response and impact of previous radiotherapy. Acta OncolÃ³gica, 2021, 60, 149-156.	0.8	5
32	The Immune Landscape of Human Primary Lung Tumors Is Th2 Skewed. Frontiers in Immunology, 2021, 12, 764596.	2.2	31
33	Proteogenomics of non-small cell lung cancer reveals molecular subtypes associated with specific therapeutic targets and immune-evasion mechanisms. Nature Cancer, 2021, 2, 1224-1242.	5.7	37
34	A 10â€year prediagnostic followâ€up study shows that serum RNA signals are highly dynamic in lung carcinogenesis. Molecular Oncology, 2020, 14, 235-247.	2.1	16
35	Responses in the diffusivity and vascular function of the irradiated normal brain are seen up until 18 months following SRS of brain metastases. Neuro-Oncology Advances, 2020, 2, vdaa028.	0.4	5
36	Protein Kinase C Isozymes Associated With Relapse Free Survival in Non-Small Cell Lung Cancer Patients. Frontiers in Oncology, 2020, 10, 590755.	1.3	6

#	Article	IF	Citations
37	Breast Cancer Polygenic Risk Score and Contralateral Breast Cancer Risk. American Journal of Human Genetics, 2020, 107, 837-848.	2.6	39
38	Epigeneticâ€“smoking interaction reveals histologically heterogeneous effects of TRIM27 DNA methylation on overall survival among earlyâ€stage NSCLC patients. Molecular Oncology, 2020, 14, 2759-2774.	2.1	13
39	1350P Real-world treatment outcomes with brigatinib in patients with pretreated ALK+ metastatic non-small cell lung cancer (mNSCLC). Annals of Oncology, 2020, 31, S866.	0.6	0
40	1403P EGFR-mutation testing and TKI treatment patterns in locally advanced or metastatic NSCLC in Norway: A nationwide cohort study. Annals of Oncology, 2020, 31, S889.	0.6	0
41	The immune microenvironment in typical carcinoid lung tumour, a brief report of four cases. Scandinavian Journal of Immunology, 2020, 92, e12893.	1.3	6
42	Molecular characterisation of <scp>TP53</scp> mutated squamous cell carcinomas of the lung to identify putative targets for therapy. International Journal of Cancer, 2020, 147, 2957-2966.	2.3	8
43	Radiotherapy-related lymphopenia in patients with advanced non-small cell lung cancer receiving palliative radiotherapy. Clinical and Translational Radiation Oncology, 2020, 22, 15-21.	0.9	14
44	Osimertinib in T790M-positive and -negative patients with EGFR-mutated advanced non-small cell lung cancer (the TREM-study). Lung Cancer, 2020, 143, 27-35.	0.9	42
45	Independent Validation of Early-Stage Non-Small Cell Lung Cancer Prognostic Scores Incorporating Epigenetic and Transcriptional Biomarkers With Gene-Gene Interactions and Main Effects. Chest, 2020, 158, 808-819.	0.4	26
46	Antibody combinations for optimized staining of macrophages in human lung tumours. Scandinavian Journal of Immunology, 2020, 92, e12889.	1.3	16
47	362â€…A PhII study of bemcentinib, a first-in-class selective AXL kinase inhibitor, in combination with pembrolizumab in pts with previously-treated advanced NSCLC: Updated clinical & translational analysis. , 2020, 8, A387-A387.		2
48	Epigenome-wide geneâ€“age interaction analysis reveals reversed effects of PRODH DNA methylation on survival between young and elderly early-stage NSCLC patients. Aging, 2020, 12, 10642-10662.	1.4	8
49	Radiation pneumonitis (RP) after stereotactic body radiation therapy (SBRT) for early-stage non-small cell lung cancer (NSCLC): A prospective, observational study.. Journal of Clinical Oncology, 2020, 38, e21065-e21065.	0.8	0
50	Noise dependency in vascular parameters from combined gradient-echo and spin-echo DSC MRI. Physics in Medicine and Biology, 2020, 65, 225020.	1.6	4
51	OC-0095: Timing of immunotherapy and SRS â€“ Does it affects the outcome of patients with brain metastases?. Radiotherapy and Oncology, 2020, 152, S43-S44.	0.3	0
52	Mapping Bone Marrow Response in the Vertebral Column by Positron Emission Tomography Following Radiotherapy and Erlotinib Therapy of Lung Cancer. Molecular Imaging and Biology, 2019, 21, 391-398.	1.3	4
53	Increase in curative treatment and survival of lung cancer in Norway 2001â€“2016. European Journal of Epidemiology, 2019, 34, 951-955.	2.5	12
54	Efficacy results of selective AXL inhibitor bemcentinib with pembrolizumab following chemo in patients with NSCLC. Annals of Oncology, 2019, 30, v649-v650.	0.6	2

#	Article	IF	Citations
55	Identification of microRNAs involved in pathways which characterize the expression subtypes of NSCLC. Molecular Oncology, 2019, 13, 2604-2615.	2.1	11
56	PO-1000 Vascular responses in normal brain tissue after combined immunotherapy and SRS to brain metastases. Radiotherapy and Oncology, 2019, 133, S551-S552.	0.3	1
57	EGLN2 DNA methylation and expression interact with HIF1A to affect survival of early-stage NSCLC. Epigenetics, 2019, 14, 118-129.	1.3	28
58	A Longitudinal Study of the Association between Mammographic Density and Gene Expression in Normal Breast Tissue. Journal of Mammary Gland Biology and Neoplasia, 2019, 24, 163-175.	1.0	3
59	Utilization rates of stereotactic body radiation therapy for the treatment of stage I NSCLC in three European countries. Annals of Oncology, 2019, 30, ii27-ii28.	0.6	2
60	The immune microenvironment in nonâ€small cell lung cancer is predictive of prognosis after surgery. Molecular Oncology, 2019, 13, 1166-1179.	2.1	57
61	SIPA1L3 methylation modifies the benefit of smoking cessation on lung adenocarcinoma survival: an epigenomicâ€“smoking interaction analysis. Molecular Oncology, 2019, 13, 1235-1248.	2.1	19
62	EMT network-based feature selection improves prognosis prediction in lung adenocarcinoma. PLoS ONE, 2019, 14, e0204186.	1.1	6
63	P2.04-74 Radiotherapy Prior to Immunotherapy Is Associated with Durable Disease Control in Advanced NSCLC. Journal of Thoracic Oncology, 2019, 14, S737-S738.	0.5	0
64	EP1.18-12 The Neutrophil and Platelet to Lymphocyte Ratios and Glasgow Prognostic Score as a Predictor for Relapse After Stereotactic Radiation for Lung Cancer. Journal of Thoracic Oncology, 2019, 14, S1101.	0.5	0
65	OA02.07 Phase 3 ALUR Study of Alectinib in Pretreated ALK+ NSCLC: Final Efficacy, Safety and Targeted Genomic Sequencing Analyses. Journal of Thoracic Oncology, 2019, 14, S210.	0.5	8
66	P1.01-72 A Phase II Study of Selective AXL Inhibitor Bemcentinib and Pembrolizumab in Patients with NSCLC Refractory to Anti-PD(L)1. Journal of Thoracic Oncology, 2019, 14, S388.	0.5	2
67	MA03.06 Efficacy Results of Selective AXL Inhibitor Bemcentinib with Pembrolizumab Following Chemotherapy in Patients with NSCLC. Journal of Thoracic Oncology, 2019, 14, S258-S259.	0.5	2
68	PathTracer: High-sensitivity detection of differential pathway activity in tumours. Scientific Reports, 2019, 9, 16332.	1.6	2
69	Trans-omics biomarker model improves prognostic prediction accuracy for early-stage lung adenocarcinoma. Aging, 2019, 11, 6312-6335.	1.4	13
70	Treatment beyond RECIST-defined progression in relapsed EGFR-mutated non-small cell lung cancer (NSCLC) patients treated with 2nd line osimertinib.. Journal of Clinical Oncology, 2019, 37, e20544-e20544.	0.8	0
71	Molecular characteristics in lung squamous cell carcinomas dependent on TP53 status: Putative targets. Annals of Oncology, 2019, 30, v789.	0.6	0
72	Serum cytokine profiles and metabolic tumor burden in patients with non-small cell lung cancer undergoing palliative thoracic radiation therapy. Advances in Radiation Oncology, 2018, 3, 130-138.	0.6	6

#	Article	IF	Citations
73	Circulating microRNAs associated with prolonged overall survival in lung cancer patients treated with nivolumab. Acta OncolÃ³gica, 2018, 57, 1225-1231.	0.8	59
74	A multiâ€omic study reveals BTG2 as a reliable prognostic marker for earlyâ€stage nonâ€small cell lung cancer. Molecular Oncology, 2018, 12, 913-924.	2.1	31
75	Alectinib versus chemotherapy in crizotinib-pretreated anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer: results from the phase III ALUR study. Annals of Oncology, 2018, 29, 1409-1416.	0.6	238
76	Epigenetic modifications in KDM lysine demethylases associate with survival of early-stage NSCLC. Clinical Epigenetics, 2018, 10, 41.	1.8	12
77	Nâ€glycan signatures identified in tumor interstitial fluid and serum of breast cancer patients: association with tumor biology and clinical outcome. Molecular Oncology, 2018, 12, 972-990.	2.1	24
78	Integrative genomic profiling of large-cell neuroendocrine carcinomas reveals distinct subtypes of high-grade neuroendocrine lung tumors. Nature Communications, 2018, 9, 1048.	5.8	254
79	P3.03-26 Tumor Immune Microenvironment in NSCLC is Predictive of Prognosis After Surgery. Journal of Thoracic Oncology, 2018, 13, S920.	0.5	0
80	MA21.06 Proteins Associated with Survival Differ Depending on Molecular Subtypes, and Mutational- and Smoking-Status In NSCLC Biopsies. Journal of Thoracic Oncology, 2018, 13, S431.	0.5	0
81	Atezolizumab Treatment Beyond Progression in Advanced NSCLC: Results From the Randomized, Phase III OAK Study. Journal of Thoracic Oncology, 2018, 13, 1906-1918.	0.5	88
82	DNA Methylation of LRRC3B: A Biomarker for Survival of Early-Stage Nonâ€“Small Cell Lung Cancer Patients. Cancer Epidemiology Biomarkers and Prevention, 2018, 27, 1527-1535.	1.1	10
83	Brain metastases with poor vascular function are susceptible to pseudoprogression after stereotactic radiation surgery. Advances in Radiation Oncology, 2018, 3, 559-567.	0.6	13
84	Levels and prognostic impact of circulating markers of inflammation, endothelial activation and extracellular matrix remodelling in patients with lung cancer and chronic obstructive pulmonary disease. BMC Cancer, 2018, 18, 739.	1.1	27
85	Intratumor heterogeneity defines treatmentâ€resistant <scp>HER</scp>2+ breast tumors. Molecular Oncology, 2018, 12, 1838-1855.	2.1	74
86	Substantial nation-wide improvement in lung cancer relative survival in Norway from 2000 to 2016. Lung Cancer, 2018, 122, 138-145.	0.9	30
87	Immune Cell Composition in Human Non-small Cell Lung Cancer. Frontiers in Immunology, 2018, 9, 3101.	2.2	202
88	Long term effect of nivolumab in patients with non-small cell lung cancer.. Journal of Clinical Oncology, 2018, 36, e21156-e21156.	0.8	0
89	Rapid drop in blood platelet count and increase in creatinine in non-small cell lung cancer (NSCLC) patients treated with osimertinib.. Journal of Clinical Oncology, 2018, 36, e21026-e21026.	0.8	2
90	Characteristics of radiation pneumonitis and lung function after curatively intended radiotherapy in non-small cell lung carcinoma. , 2018, , .		0

#	Article	IF	Citations
91	Profiling of micro<scp>RNA</scp>s in tumor interstitial fluid of breast tumors â€“ a novel resource to identify biomarkers for prognostic classification and detection of cancer. Molecular Oncology, 2017, 11, 220-234.	2.1	50
92	Real-world data on nivolumab treatment of non-small cell lung cancer. Acta OncolÃ³gica, 2017, 56, 438-440.	0.8	42
93	P2.01-002 Serum Protein Signature in Lung Cancer Patients and in Patients with Chronic Obstructive Pulmonary Disease. Journal of Thoracic Oncology, 2017, 12, S783-S784.	0.5	0
94	PUB050 Identification of Proteins Associated by Mutation Status in Non Small-Cell Lung Cancer Biopsies. Journal of Thoracic Oncology, 2017, 12, S1477.	0.5	0
95	High number of kinomeâ€mutations in nonâ€small cell lung cancer is associated with reduced immune response and poor relapseâ€free survival. International Journal of Cancer, 2017, 141, 184-190.	2.3	14
96	PIK3CA mutations as prognostic factor in squamous cell lung carcinoma. Lung Cancer, 2017, 103, 52-57.	0.9	28
97	A new method to assess pulmonary changes using ¹⁸F-fluoro-2-deoxyglucose positron emission tomography for lung cancer patients following radiotherapy. Acta OncolÃ³gica, 2017, 56, 1597-1603.	0.8	6
98	Dabrafenib plus trametinib in patients with previously untreated BRAFV600E-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial. Lancet Oncology, The, 2017, 18, 1307-1316.	5.1	889
99	Assessment of pulmonary 18 F-FDG-PET uptake and cytokine profiles in non-small cell lung cancer patients treated with radiotherapy and erlotinib. Clinical and Translational Radiation Oncology, 2017, 4, 57-63.	0.9	8
100	Pan-cancer analysis of somatic copy-number alterations implicates IRS4 and IGF2 in enhancer hijacking. Nature Genetics, 2017, 49, 65-74.	9.4	326
101	Phase 2 trial (BRF113928) of dabrafenib (D) plus trametinib (T) in patients (pts) with previously untreated BRAF V600Eâ€mutant metastatic non-small cell lung cancer (NSCLC). Annals of Oncology, 2017, 28, v637.	0.6	4
102	Evaluation of Prognostic and Predictive Significance of Circulating MicroRNAs in Ovarian Cancer Patients. Disease Markers, 2017, 2017, 1-9.	0.6	44
103	Impact of atezolizumab (atezo) treatment beyond disease progression (TBP) in advanced NSCLC: Results from the randomized phase III OAK study.. Journal of Clinical Oncology, 2017, 35, 9001-9001.	0.8	16
104	NSCLC depend upon YAP expression and nuclear localization after acquiring resistance to EGFR inhibitors. Genes and Cancer, 2017, 8, 497-504.	0.6	47
105	DNA methylation signature (SAM40) identifies subgroups of the Luminal A breast cancer samples with distinct survival. Oncotarget, 2017, 8, 1074-1082.	0.8	16
106	Data-driven analysis of immune infiltrate in a large cohort of breast cancer and its association with disease progression, ER activity, and genomic complexity. Oncotarget, 2017, 8, 57121-57133.	0.8	31
107	TP53 Mutation Spectrum in Smokers and Never Smoking Lung Cancer Patients. Frontiers in Genetics, 2016, 07, 85.	1.1	76
108	A unique set of 6 circulating microRNAs for early detection of non-small cell lung cancer. Oncotarget, 2016, 7, 37250-37259.	0.8	77

#	Article	IF	Citations
109	Subtypeâ€specific microâ€RNA expression signatures in breast cancer progression. International Journal of Cancer, 2016, 139, 1117-1128.	2.3	53
110	Detection of disseminated tumor cells in lymph nodes from patients with early stage non-small cell lung cancer. Diagnostic Pathology, 2016, 11, 50.	0.9	10
111	Non-small cell lung cancer is characterised by a distinct inflammatory signature in serum compared with chronic obstructive pulmonary disease. Clinical and Translational Immunology, 2016, 5, e109.	1.7	26
112	MicroRNA-profiles in lung adenocarcinomas. Expert Review of Precision Medicine and Drug Development, 2016, 1, 469-474.	0.4	0
113	rs2735383, located at a microRNA binding site in the 3â€™UTR of NBS1, is not associated with breast cancer risk. Scientific Reports, 2016, 6, 36874.	1.6	2
114	Cytokine profiling of tumor interstitial fluid of the breast and its relationship with lymphocyte infiltration and clinicopathological characteristics. OncoImmunology, 2016, 5, e1248015.	2.1	48
115	The MYCN-HMGA2-CDKN2A pathway in non-small cell lung carcinomaâ€”differences in histological subtypes. BMC Cancer, 2016, 16, 71.	1.1	14
116	Breast cancer risk variants at 6q25 display different phenotype associations and regulate ESR1, RMND1 and CCDC170. Nature Genetics, 2016, 48, 374-386.	9.4	125
117	Genomeâ€wide DNA methylation analyses in lung adenocarcinomas: Association with EGFR, KRAS and TP53 mutation status, gene expression and prognosis. Molecular Oncology, 2016, 10, 330-343.	2.1	81
118	Strategies for clinical implementation of TNM-Immunoscore in resected nonsmall-cell lung cancer. Annals of Oncology, 2016, 27, 225-232.	0.6	147
119	EGFR mutation testing of lung cancer patients â€“ Experiences from Vestfold Hospital Trust. Acta OncolÃ³gica, 2016, 55, 149-155.	0.8	9
120	C-reactive protein (CRP) as a predictive marker for immunotherapy in lung cancer.. Journal of Clinical Oncology, 2016, 34, e20623-e20623.	0.8	11
121	Rituximab efficiently depletes B cells in lung tumorsÂand normal lung tissue. F1000Research, 2016, 5, 38.	0.8	15
122	Abstract 1471: Immunotherapy revised: Ipilimumab potentiates the vascular response to stereotactic radiosurgery in patients with brain metastases. , 2016, , .		0
123	Targeted Disruption of ALK Reveals a Potential Role in Hypogonadotropic Hypogonadism. PLoS ONE, 2015, 10, e0123542.	1.1	24
124	NUT expression in primary lung tumours. Diagnostic Pathology, 2015, 10, 156.	0.9	7
125	Targeting lung cancer through inhibition of checkpoint kinases. Frontiers in Genetics, 2015, 6, 70.	1.1	24
126	Dose painting by numbers in a standard treatment planning system using inverted dose prescription maps. Acta OncolÃ³gica, 2015, 54, 1607-1613.	0.8	21

#	Article	IF	Citations
127	Polymorphisms in a Putative Enhancer at the 10q21.2 Breast Cancer Risk Locus Regulate NRBF2 Expression. American Journal of Human Genetics, 2015, 97, 22-34.	2.6	37
128	Identification of novel fusion genes in lung cancer using breakpoint assembly of transcriptome sequencing data. Genome Biology, 2015, 16, 7.	3.8	44
129	Glycanâ€related gene expression signatures in breast cancer subtypes; relation to survival. Molecular Oncology, 2015, 9, 861-876.	2.1	47
130	Stromal CD8+ T-cell Densityâ€"A Promising Supplement to TNM Staging in Nonâ€"Small Cell Lung Cancer. Clinical Cancer Research, 2015, 21, 2635-2643.	3.2	269
131	Prevalence and Prognostic Significance of Sodium-Dependent Phosphate Transporter 2B (Napi2B) Protein Expression in Non-Small Cell Lung Cancer (Nsclc). Annals of Oncology, 2014, 25, iv66.	0.6	8
132	Rapid reduction in the incidence of cancer of unknown primary. A population-based study. Acta OncolÃ³gica, 2014, 53, 134-137.	0.8	26
133	Years of life lost as a measure of cancer burden on a national level. British Journal of Cancer, 2014, 111, 1014-1020.	2.9	77
134	Unique microRNAâ€profiles in EGFR â€mutated lung adenocarcinomas. International Journal of Cancer, 2014, 135, 1812-1821.	2.3	61
135	Genome-wide DNA methylation profiles in progression to in situand invasive carcinoma of the breast with impact on gene transcription and prognosis. Genome Biology, 2014, 15, 435.	3.8	147
136	GoIFISH: a system for the quantification of single cell heterogeneity from IFISH images. Genome Biology, 2014, 15, 442.	3.8	8
137	Inference of Tumor Evolution during Chemotherapy by Computational Modeling and In Situ Analysis of Genetic and Phenotypic Cellular Diversity. Cell Reports, 2014, 6, 514-527.	2.9	239
138	Human papilloma virus detection and typing in 334 lung cancer patients. Acta OncolÃ³gica, 2014, 53, 952-957.	0.8	18
139	Differential DNA methylation analysis of breast cancer reveals the impact of immune signaling in radiation therapy. International Journal of Cancer, 2014, 135, 2085-2095.	2.3	28
140	463: A molecular study of breast cancer progression stages from normal breast tissue to invasive cancer. European Journal of Cancer, 2014, 50, S112.	1.3	0
141	Frequent mutations in chromatin-remodelling genes in pulmonary carcinoids. Nature Communications, 2014, 5, 3518.	5.8	239
142	BRAF-mutations in non-small cell lung cancer. Lung Cancer, 2014, 84, 36-38.	0.9	70
143	Association of N-Glycosylation with Breast Carcinoma and Systemic Features Using High-Resolution Quantitative UPLC. Journal of Proteome Research, 2014, 13, 2314-2327.	1.8	123
144	Genome-wide DNA methylation profiles in progression to. Genome Biology, 2014, 15, 435.	13.9	105

#	Article	IF	Citations
145	PIK3CA as a prognostic marker in non-small cell lung cancer of squamous cell carcinoma type.. Journal of Clinical Oncology, 2014, 32, 8105-8105.	0.8	0
146	Mutations in NSCLC.. Journal of Clinical Oncology, 2014, 32, e18516-e18516.	0.8	0
147	Osteopontin is a prognostic biomarker in non-small cell lung cancer. BMC Cancer, 2013, 13, 540.	1.1	45
148	Clinical significance of disseminated tumour cells in non-small cell lung cancer. British Journal of Cancer, 2013, 109, 1264-1270.	2.9	18
149	Two Distinct Categories of Focal Deletions in Cancer Genomes. PLoS ONE, 2013, 8, e66264.	1.1	34
150	High Levels of Genomic Aberrations in Serous Ovarian Cancers Are Associated with Better Survival. PLoS ONE, 2013, 8, e54356.	1.1	22
151	Novel Molecular Tumor Cell Markers in Regional Lymph Nodes and Blood Samples from Patients Undergoing Surgery for Non-Small Cell Lung Cancer. PLoS ONE, 2013, 8, e62153.	1.1	12
152	Abstract 1962: Differentially expressed microRNAs in adenocarcinomas of the lung and tumor-adjacent normal lung tissue.. , 2013, , .		0
153	Abstract 2398: KRAS mutation status is a strong prognostic factor in some but not all subtypes of non-small cell lung cancer.. , 2013, , .		0
154	Abstract C47: Inference of tumor evolution during chemotherapy by computational modeling and single cell analysis of diversity.. , 2013, , .		0
155	Dosimetric impact of a frame-based strategy in stereotactic radiotherapy of lung tumors. Acta OncolÃ³gica, 2012, 51, 603-609.	0.8	7
156	Clinicopathological Characteristics of 11 NSCLC Patients with EGFR-Exon 20 Mutations. Journal of Thoracic Oncology, 2012, 7, 1471-1473.	0.5	55
157	Integrated molecular profiles of invasive breast tumors and ductal carcinoma in situ (DCIS) reveal differential vascular and interleukin signaling. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 2802-2807.	3.3	149
158	AXL Expression and Risk of Relapse in Non-Small Cell Lung Cancer. American Journal of Clinical Pathology, 2012, 138, A146-A146.	0.4	0
159	Increasing Age and Carcinoma Not Otherwise Specified: A 20-Year Population Study of 40,118 Lung Cancer Patients. Journal of Thoracic Oncology, 2012, 7, 57-63.	0.5	9
160	Incidence and Survival of Malignant Pleural Mesothelioma in Norway: A Population-Based Study of 1686 Cases. Journal of Thoracic Oncology, 2012, 7, 1858-1861.	0.5	30
161	Abstract P3-05-04: Intra-tumor heterogeneity as a predictor of therapy response in HER2 positive breast cancer. Cancer Research, 2012, 72, P3-05-04-P3-05-04.	0.4	3
162	Dynamic respiratory gated18FDG-PET of lung tumors â€“ a feasibility study. Acta OncolÃ³gica, 2011, 50, 889-896.	0.8	6

#	Article	IF	Citations
163	Serum estradiol levels associated with specific gene expression patterns in normal breast tissue and in breast carcinomas. BMC Cancer, 2011, 11, 332.	1.1	35
164	Mutations in the DDR2 Kinase Gene Identify a Novel Therapeutic Target in Squamous Cell Lung Cancer. Cancer Discovery, 2011, 1, 78-89.	7.7	455
165	Deregulation of MYCN, LIN28B and LET7 in a Molecular Subtype of Aggressive High-Grade Serous Ovarian Cancers. PLoS ONE, 2011, 6, e18064.	1.1	172
166	Palmar Bullous Blistering Induced by Erlotinib. Journal of Thoracic Oncology, 2011, 6, 954.	0.5	2
167	EGFR Gene Alterations in a Norwegian Cohort of Lung Cancer Patients Selected for Surgery. Journal of Thoracic Oncology, 2011, 6, 947-950.	0.5	48
168	Gene expression profiles of breast biopsies from healthy women identify a group with claudin-low features. BMC Medical Genomics, 2011, 4, 77.	0.7	38
169	Sex-specific trends in lung cancer incidence and survival: a population study of 40 118 cases. Thorax, 2011, 66, 301-307.	2.7	123
170	Stereotactic Body Radiation Therapy Is Effective and Safe in Patients with Early-Stage Non-Small Cell Lung Cancer with Low Performance Status and Severe Comorbidity. Case Reports in Oncology, 2011, 4, 25-34.	0.3	24
171	Abstract 343: Molecular markers for detection of micrometastases in regional lymph nodes from patients undergoing surgery for non-small cell lung cancer. , 2011, , .		0
172	Excessive Soft Tissue Reaction after Stereotactic Body Radiation Therapy in a Woman with Four Different Cancer Diagnoses. Case Reports in Oncology, 2010, 3, 195-201.	0.3	0
173	Glycan gene expression signatures in normal and malignant breast tissue; possible role in diagnosis and progression. Molecular Oncology, 2010, 4, 98-118.	2.1	147
174	398 Glycan gene expression signatures distinguish normal and malignant breast tissue; possible role in diagnosis and progression. European Journal of Cancer, Supplement, 2010, 8, 102.	2.2	1
175	Expression levels of uridine 5'-diphospho-glucuronosyltransferase genes in breast tissue from healthy women are associated with mammographic density. Breast Cancer Research, 2010, 12, R65.	2.2	37
176	Abstract 877: Impact of histology and gender on lung cancer survival: a population based study. , 2010, , .		0
177	Methylation detection oligonucleotide microarray analysis: a high-resolution method for detection of CpG island methylation. Nucleic Acids Research, 2009, 37, e89-e89.	6.5	19
178	TP53 codon 72 polymorphism and cervical cancer: a pooled analysis of individual data from 49 studies. Lancet Oncology, The, 2009, 10, 772-784.	5.1	133
179	Lysophosphatidic Acid-Induced Transcriptional Profile Represents Serous Epithelial Ovarian Carcinoma and Worsened Prognosis. PLoS ONE, 2009, 4, e5583.	1.1	41
180	533 POSTER No genomic changes in mammographically dense breast. European Journal of Cancer, Supplement, 2007, 5, 99.	2.2	0

#	Article	IF	Citations
181	TP53 mutations and codon 72 genotypeâ€"impact on survival among ovarian cancer patients. Annals of Oncology, 2007, 18, 964-966.	0.6	5
182	B4-05: Development of a serum marker panel for early lung cancer detection and treatment response assessment using the proximity-ligation assay (PLA). Journal of Thoracic Oncology, 2007, 2, S345.	0.5	4
183	Germline glutathione S-transferase variants in breast cancer: Relation to diagnosis and cutaneous long-term adverse effects after two fractionation patterns of radiotherapy. International Journal of Radiation Oncology Biology Physics, 2007, 67, 1163-1171.	0.4	43
184	Radiation-induced effects on gene expression: An in vivo study on breast cancer. Radiotherapy and Oncology, 2006, 80, 230-235.	0.3	22
185	Gene Expression Programs in Response to Hypoxia: Cell Type Specificity and Prognostic Significance in Human Cancers. PLoS Medicine, 2006, 3, e47.	3.9	536
186	PIK3CA mutations in advanced ovarian carcinomas. Human Mutation, 2005, 25, 322-322.	1.1	94
187	Protein Expression and Prognostic Value of Genes in the erb-b Signaling Pathway in Advanced Ovarian Carcinomas. American Journal of Clinical Pathology, 2005, 124, 392-401.	0.4	46
188	TP53 mutations among molecular subtypes of HER2-positive tumors. Breast Cancer Research, 2005, 7, 1.	2.2	0
189	TP53 mutations in early-stage ovarian carcinoma, relation to long-term survival. British Journal of Cancer, 2004, 90, 678-685.	2.9	53
190	Effect of the codon 72 polymorphism (c.215G>C, p.Arg72Pro) in combination with somatic sequence variants in theTP53gene on survival in patients with advanced ovarian carcinoma. Human Mutation, 2004, 24, 21-34.	1.1	46
191	X chromosome inactivation in cervical cancer patients. Cancer Genetics and Cytogenetics, 2003, 146, 73-76.	1.0	13
192	Fibroblast Growth Factor Receptor 3 (FGFR3)â€"Analyses of the S249C Mutation and Protein Expression in Primary Cervical Carcinomas. Analytical Cellular Pathology, 2001, 23, 45-49.	2.1	12
193	Primary cervical carcinomas show 2 common regions of deletion at 3P, 1 within theFHIT gene: Evaluation of allelic imbalance atFHIT, RB1 andTP53 in relation to survival. International Journal of Cancer, 2000, 88, 217-222.	2.3	16
194	Allelic imbalance at chromosome region 11q23 in cervical carcinomas. European Journal of Cancer, 1999, 35, 659-663.	1.3	11
195	p53 polymorphism and cervical cancer. Lancet, The, 1999, 354, 1561-1562.	6.3	4
196	p53 polymorphism and risk of cervical cancer. Nature, 1998, 396, 530-531.	13.7	113
197	Mutations in the TP53 gene and protein expression of p53, MDM 2 and p21/WAF-1 in primary cervical carcinomas with no or low human papillomavirus load. British Journal of Cancer, 1998, 78, 69-72.	2.9	27
198	An increased risk of cervical intra-epithelial neoplasia grade II-III among human papillomavirus positive patients with theHLA-DQA1*0102-DQB1*0602 haplotype: A population-based caseâ€"control study of Norwegian women. , 1998, 76, 19-24.		46

#	Article	IF	Citations
199	Microsatellite instability in cervical and endometrial carcinomas. International Journal of Cancer, 1997, 70, 499-501.	2.3	64
200	TP53 gene mutations and protein accumulation in primary vaginal carcinomas. British Journal of Cancer, 1995, 72, 129-133.	2.9	11
201	DQA1 and DQB1 genes in patients with squamous cell carcinoma of the cervix: relationship to human papillomavirus infection and prognosis. Cancer Epidemiology Biomarkers and Prevention, 1994, 3, 479-86.	1.1	5
202	Immunohistochemical analysis of p53 protein overexpression in normal, premalignant, and malignant tissues of the cervix uteri. Journal of Pathology, 1993, 169, 21-26.	2.1	62
203	Genetic alterations of the TP53 gene, p53 protein expression and hpv infection in primary cervical carcinomas. Journal of Pathology, 1993, 171, 105-114.	2.1	77
204	Papillomaviruses, p53, and cervical cancer. Lancet, The, 1992, 339, 1350-1351.	6.3	49
205	TP53 mutation and HPV-infection in primary cervical carcinomas. Cancer Genetics and Cytogenetics, 1992, 63, 116.	1.0	2
206	HLA antigens and cervical carcinoma. Nature, 1992, 356, 23-23.	13.7	53
207	Papillomaviruses, p53, and cervical cancer. Lancet, The, 1992, 339, 1350-1.	6.3	11